Genetic elements driving IMiD resistance in multiple myeloma - 101793

Spotlight
Video

Genetic elements driving IMiD resistance in multiple myeloma

VJHemOnc has 1444 videos Subscribe Here

Loading........
Description: Immunomodulatory drugs (IMiDs) are a class of drugs including the likes of thalidomide, which are used in the treatment of cancers such as multiple myeloma (MM). In this interview, recorded at the Myeloma 2017 meeting in Edinburgh, UK, Benjamin Barwick, MD, of Emory University, Atlanta, GA, discusses the talks given at the meeting which discussed IMiDs, and how resistance to them in MM can be driven by various enhancers and transcription factors that lead to worse outcomes for patients.
Shared By : VJHemOnc
Posted on : 12/06/17
Added : 9 months ago
Category : Multiple Myeloma